A clinical study to evaluate IRL201104 for the treatment of COVID-19 related Acute Respiratory Distress Syndrome (ARDS)
Latest Information Update: 14 Feb 2022
Price :
$35 *
At a glance
- Drugs IRL 201104 (Primary)
- Indications Adult respiratory distress syndrome; COVID 2019 infections
- Focus Adverse reactions
- 10 Jul 2020 New trial record